Financials Notes to the company financial statements 1 Accounting policies The accounting policies adopted in the preparation of these Company financial statements are the same as those set out in note 2 to the Group financial statements with the addition of the following: Investments Investments in subsidiaries are stated at cost less provision for impairment.
Share-based payments The Company has elected to apply IFRS2 to all share-based awards and options granted post 7 November 2002 that had not vested by 1 January 2005.
The carrying amount of an investment in a subsidiary is increased to the extent that share-based payments relate to employees of that subsidiary.
Share-based payment expenses relating to employees of the Company are expensed within the income statement.
These policies have been applied consistently to the periods presented.
The functional currency of the Company is Sterling and all values are rounded to the nearest 0.1m except where otherwise indicated.
2 Profit for the period As permitted by section 408 of the Companies Act 2006, the Company has elected not to present its own income statement for the year.
The loss after tax of the Company amounted to 2.8m 2010: profit of 0.4m.
The auditors remuneration for audit services to the Company, payable to KPMG Audit Plc, was 123,000 2010: 85,000.
In addition, the Company made payments for services relating to due diligence related to corporate finance transactions entered into or proposed to be entered into by the Company of 380,000 and additional payments of 64,000 2010: 212,000 in relation to other services, being the review of the interim accounts, other accounting advice and advice on employee benefit matters.
3 Staff costs The employees are based in the UK.
Disclosures of individual directors remuneration and associated costs required by the Companies Act 2006 and specified by the Financial Services Authority are on pages 57 to 68 within the remuneration report and form part of these audited accounts.
The employees of the Company are members of the Group pension plans as detailed in note 29 of the Group financial statements.
The Company receives a charge based upon the employer contribution to the Groups defined benefit pension plan.
No additional contributions are paid by the Company.
4 Dividend The directors do not propose to declare a dividend for the year 2010: nil.
131 BTG plc Annual Report and Accounts 2011 Financials Notes to the company financial statements continued 5 Investment in subsidiary undertakings m Cost At 1 April 2009 189.6 Acquisition of Protherics PLC 2.0 Share-based payments 0.4 At 1 April 2010 192.0 Acquisition of Biocompatibles International plc 171.8 Share-based payments 0.6 At 31 March 2011 364.4 A list of the Companys principal subsidiary undertakings is shown in note 37 to the Group financial statements.
The acquisition of Biocompatibles International plc is outlined in note 38 of the Group financial statements.
6 Trade and other receivables 31 March 31 March 2011 2010 m m Due within one year Amounts owed by subsidiary undertakings 218.4 231.9 218.4 231.9 7 Capital and reserves Share Share Merger Retained capital premium reserve earnings Total m m m m m At 1 April 2009 25.5 187.3 156.5 40.7 410.0 Profit for year 0.4 0.4 Total comprehensive income for the year 0.4 0.4 Movement in shares held by Trust 0.3 0.3 Issued on acquisition of Protherics 0.2 1.6 1.8 Other share capital issued 0.1 0.8 0.9 Share-based payments 1.1 1.1 At 31 March 2010 25.8 188.1 158.1 42.5 414.5 Loss for year 2.8 2.8 Total comprehensive income gains for the year 2.8 2.8 Movement in shares held by Trust 0.5 0.5 Issued on acquisition of Biocompatibles 6.9 159.7 166.6 Other share capital issued 0.1 0.1 Share-based payments 0.6 0.6 At 31 March 2011 32.7 188.2 317.8 39.8 578.5 S ee note 38 to the Group financial statements.
132 Financials BTG plc Annual Report and Accounts 2011 Financials 7 Capital and reserves continued The merger reserve is used where more than 90% of the shares in a subsidiary are acquired and the consideration includes the issue of new shares by the Company, thereby attracting merger relief under s612 and s613 of the Companies Act 2006.
The balance on the merger reserve has arisen through: 1 The acquisition of Protherics PLC on 4 December 2008 and includes directly attributable costs of issuing the shares of 0.4m.
2 The acquisition of Biocompatibles International plc on 27 January 2011 and includes directly attributable costs of issuing of shares of 1.1m.
Details of Company share capital are disclosed in note 24 to the Group financial statements.
Details of share options granted by the Company are set out in note 30 to the Group financial statements.
Details of shares in the Company held by subsidiaries are shown in note 31 to the Group financial statements.
8 Trade and other payables 31 March 31 March 2011 2010 m m Amounts falling due within one year Amounts owed to subsidiary undertakings 7.9 Accruals and deferred income 2.3 1.6 2.3 9.5 Amounts falling due after more than one year Contingent value notes 1.1 Amounts owing to subsidiary undertakings are repayable on demand.
The directors consider the fair value to be equal to the book value.
9 Financial assets and liabilities Designated Amortised Total carrying at fair value cost value Fair value m m m m 31 March 2010 Cash and cash equivalents 0.2 0.2 0.2 Trade and other receivables 231.9 231.9 231.9 Trade and other payables 9.6 9.6 9.6 31 March 2011 Cash and cash equivalents Trade and other receivables 218.4 218.4 218.4 Trade and other payables 1.1 2.3 3.4 3.4 Financial liabilities classified as designated at fair value comprise the contingent value notes details of which are disclosed in note 33 of the Group financial statements.
133 BTG plc Annual Report and Accounts 2011 Financials Notes to the company financial statements continued 9 Financial assets and liabilities continued Credit risk The Companys credit risk is the risk that one of its subsidiaries is unable to repay intercompany amounts owing.
The recoverability of the Companys intercompany receivable is considered at each balance sheet date.
Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.
The Company does not hold significant cash balances as Group cash is managed centrally within its subsidiaries.
Accordingly the Company is funded by its subsidiaries as its liabilities fall due.
Market risk Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Groups income or the value of its holdings in financial instruments.
As holding company of the BTG Group, the Company does not have significant exposure to movements in market prices and accordingly no additional disclosure is provided.
Capital management Details of the Companys objectives with respect to managing capital are disclosed in note 33 to the Group financial statements.
10 Guarantees and contingent liabilities The Company has entered into an agreement to guarantee payments under the lease of its US subsidiary undertaking.
The Company has provided a guarantee to certain subsidiary undertakings in respect of the BTG Pension Fund up to a maximum amount equal to the lowest non-negative amount which, when added to the assets of the Fund, would result in the Fund being at least 105% funded on the date on which any liability arose, calculated on the basis set out in section 179 of the Pensions Act 2004, were a valuation to be conducted as at that date.
The Company has also provided a guarantee to the same subsidiary undertakings for a maximum amount of 12.7m being the deficit repair contributions agreed with the Trustees of the Scheme following the finalisation of the last actuarial valuation.
The Guarantee reduces as payments are made and expires on 31 January 2013.
11 Related-party transactions The Company has a related-party relationship with its subsidiary undertakings and its directors.
In relation to the related-party relationship identified on page 49 concerning Giles Kerr, payments made by BTG to Oxford University and Isis Innovations Ltd under the relevant licence agreements were 1.8m during the year ended 31 March 2011.
There are no amounts still outstanding and payable by BTG under these agreements as at 31 March 2011.
In relation to the related-party relationship identified on page 49 concerning Melanie Lee, payments made by BTG to Cancer Research Technology Ltd under the relevant licence agreements were 0.1m during the year ended 31 March 2011.
Key management personnel are considered to be the directors and their remuneration is disclosed within the remuneration report on pages 57 to 68.
134 Financials BTG plc Annual Report and Accounts 2011
